Recombinant Human Thyroid Stimulating Hormone

PreclinicalSmall molecule

NNanjing First Hospital, Nanjing Medical University

Recombinant Human Thyroid Stimulating Hormone is one of 43 small molecule programs targeting Thyroid Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CancerActive, not recruiting

Thyroid CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

12 2

Koselugo

AstraZeneca

Phase 3

3 3

Glucophage

EMD Serono

Phase 3

2 4

Sutent

Pfizer

Phase 2

3 5

Iclusig

Takeda

Phase 2

2 6

Stivarga

Bayer

Phase 2

1 7

Mektovi

Pfizer

Phase 2

1 8

Actos

Takeda

Phase 2

1 9

Iressa

AstraZeneca

Phase 2

1 10

Istodax

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Treatment

NCT06405217

N/ARecruiting

Thyroid Cancer

NCT06431620

Clinical

Trials by Indication[1]

Treatment1 trial

Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment

Recruiting·NNanjing First Hospital, Nanjing Medical University·N/A·NCT06405217·30 enrolled

Thyroid Cancer1 trial

Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer

Recruiting·NNanjing First Hospital, Nanjing Medical University·N/A·NCT06431620·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Recombinant Human Thyroid Stimulating Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Human Thyroid Stimulating Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Human Thyroid Stimulating Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing First Hospital, Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNanjing First Hospital, Nanjing Medical University

Recombinant Human Thyroid Stimulating Hormone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Treatment1 trial

Thyroid Cancer1 trial

References

Drug Info

Quick Facts

Related News